0 CHECKOUT

Prostate Cancer Drug Pathway Analyzer

  • ID: 2673688
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

Extra value: One year of free online updates included with this product

There are today at least 503 targeted molecular therapies known to affect more than 255 specific intracellular signaling pathways for the treatment of prostate cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 317 drug targets that are included in this drug-pathway analyzing tool. No less than 305 of these have been recorded with mutations and 58 drug targets have mutations which have been causally implicated in cancer.

Pathway Coverage
- BioCarta# 255 Pathways
- KEGG# 198 Pathways
- NCI-Nature# 247 Pathways
- NetPath# 32 Pathways

Pipeline Coverage
Marketed# 30
Registered# 1
Pre-registration# 2
Phase III# 18
Phase II# 154
Phase I# 88
Preclinical# 155
Discovery# 8
No Data# 5
Suspended# 4
Ceased# 228

The continuous identification of drug targets and pathways that are altered in cancer is not only crucial for our understanding of cancer biology, but also to search for new targets for early diagnosis and improved treatment designs. Consequently, it has never before been as important to READ MORE >

Note: Product cover images may vary from those shown
2 of 2



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Johnson & Johnson Services, Inc.
  • Sanofi S.A.
  • Astellas Pharma, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Astrazeneca PLC
  • Emergent BioSolutions, Inc.